HM 002 1005
Alternative Names: 1005; HM-002-1005Latest Information Update: 29 Jul 2024
At a glance
- Originator Hua Medicine
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 25 Apr 2024 Phase-I clinical trials in Type 2 diabetes mellitus in USA (PO) (NCT06498284)